Shin Dongho, Moon Hyong Woo, Bae Woong Jin, Ha U-Syn, Park Young Ho, Lee Eun Joo, Moon Du Geon, Kim Sae Woong
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Healthism Corporation, Suwon 16229, Republic of Korea.
Nutrients. 2024 Dec 25;17(1):24. doi: 10.3390/nu17010024.
The prevalence of urological diseases increases with age, and lower urinary tract symptoms (LUTSs) are the most common problem. Natural compounds with minimal side effects for the improvement in LUTSs are of ongoing interest. extract (SAGX) has shown potential in preclinical studies for its effects on LUTSs. This multicenter, randomized, double-blind, placebo-controlled study aimed to evaluate the efficacy and safety of SAGX in men with lower urinary tract symptoms (LUTSs) over a 12-week period. A total of 136 subjects were randomized to receive either 400 mg or 800 mg of SAGX or a placebo daily, orally. The primary outcome was the change in the International Prostate Symptom Score (IPSS). Secondary outcomes included changes in prostate-specific antigen (PSA), testosterone levels, urinary flow rate, residual urine volume, and erectile function as measured by the International Index of Erectile Function (IIEF). Both SAGX intake groups showed statistically significant improvements in total IPSS scores and several secondary outcomes compared with the placebo group. Notable improvements were observed in symptoms of incomplete emptying, frequency, intermittency, weak stream, urgency, nocturia, and quality of life scores. Erectile function, as assessed by the IIEF, also significantly improved, especially in the 400 mg SAGX intake group. No significant differences were found in PSA levels or testosterone levels. No serious adverse events leading to discontinuation of the study drug were observed in the SAGX groups. With fewer side effects than conventional treatments, SAGX is effective and safe in improving symptoms of lower urinary tract symptoms and enhancing erectile function in men.
泌尿系统疾病的患病率随年龄增长而增加,下尿路症状(LUTSs)是最常见的问题。具有最小副作用且可改善LUTSs的天然化合物一直备受关注。锯叶棕果实提取物(SAGX)在临床前研究中已显示出对LUTSs有潜在作用。这项多中心、随机、双盲、安慰剂对照研究旨在评估SAGX在12周内对患有下尿路症状(LUTSs)男性的疗效和安全性。总共136名受试者被随机分组,每天口服400毫克或800毫克的SAGX或安慰剂。主要结局指标是国际前列腺症状评分(IPSS)的变化。次要结局指标包括前列腺特异性抗原(PSA)、睾酮水平、尿流率、残余尿量的变化,以及通过国际勃起功能指数(IIEF)测量的勃起功能变化。与安慰剂组相比,两个SAGX摄入组在总IPSS评分和几个次要结局指标上均显示出统计学上的显著改善。在排尿不尽、尿频、尿间断、尿流无力、尿急、夜尿症症状以及生活质量评分方面观察到显著改善。通过IIEF评估的勃起功能也显著改善,尤其是在摄入400毫克SAGX的组中。在PSA水平或睾酮水平上未发现显著差异。在SAGX组中未观察到导致停用研究药物的严重不良事件。与传统治疗相比,SAGX副作用更少,在改善男性下尿路症状和增强勃起功能方面有效且安全。